33 / 64
Lenvatinib + Pembrolizumab in Metastatic RCC: Phase I/II Study
Pts
ORR at Wk 24,* n
(%)
All (N = 30)
19 (63)
PFS per irRECIST
100
80
Treatment naive (n = 12)
10
(83)
Previously treated
1 regimen (n = 10)
5 (50)
60
40
FS (%)
Median PFS mos: NE
≥ 2 regimens (n = 8)
4 (50)
PD‐L1 status
Positive (n = 12)
7 (58)
20
0
P
,
(95% CI: 9.9‐NE)
Negative (n = 14)
Unknown (n = 4)
10 (71)
2 (50)
*All PR per irRECIST.
0
3
6
9
12
15
Mos
Pts at Risk n
,
30
27
23
14
2
2
Lee C, et al. ESMO 2017. Abstract 847O